Sunday, 16 August 2026European Markets
ExploreSearch
ViaNews EU
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,809
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,809 facts checked against source5,205 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference

View original at finance.yahoo.com
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference Legend Biotech USA Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Patients treated earlier, after one or two prior lines of therapy, exhibited greater immune fitness and a more immunocompetent tumor microenvironment, potential biological indicators of longer progression-free survival

    80% confidence

  • Targeting multiple investigational new drug (IND) filings for oncology and autoimmune indications starting in second half 2026

    80% confidence

  • Expect company-wide operating profit in 2026

    80% confidence

  • The latest NCCN guidelines recommend talquetamab as a bridging therapy before CAR-T treatment for people with relapsed/refractory multiple myeloma to help keep patients eligible for CARVYKTI and improve outcomes

    80% confidence

  • CARVYKTI cemented its status as the undisputed leader in multiple myeloma CAR-T cell therapy, with its continued record-breaking performance culminating in the achievement of more than 10,000 patients treated earlier this year

    80% confidence

  • We're also committed to leveraging our proven CAR-T development platform to frontline multiple myeloma and promising new in vivo and allogeneic opportunities to extend our leadership in cell therapy innovation

    80% confidence

  • The Company believes cash and cash equivalents, and time deposits of approximately $1.0 billion as of September 30, 2025, will provide financial runway beyond 2026

    80% confidence

  • Triple-class-exposed patients treated with three prior lines of therapy from the CARTITUDE-1 and CARTITUDE-4 trials achieved a median progression-free survival of 50.4 months following a single infusion of CARVYKTI

    80% confidence

  • Anticipate CARVYKTI franchise FY 2025 profitability

    80% confidence

  • Legend Biotech is poised for transformative growth in 2026, as we work to achieve profitability this year by driving global adoption of CARVYKTI

    80% confidence

  • First-in-human data for in vivo dual CD20/CD19 therapy expected starting in the second half of 2026

    80% confidence
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference — Source | Via News | ViaNews EU